Ageing and Dementia

Front Matter....Pages I-VIII
Anti-oxidants and cognitive function: a review of clinical and epidemiologic studies....Pages 1-8
Brain abnormalities in the elderly: frequency and predictors in the United States (the Cardiovascular Health Study)....Pages 9-16
Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam study....Pages 17-29
The spectrum of age-associated brain abnormalities: their measurement and histopathological correlates....Pages 31-39
Cognitive correlates of cerebral white matter changes....Pages 41-67
Concepts on the prognostic significance of white matter changes....Pages 69-78
Difficulties in the clinical diagnosis of vascular dementia and dementia of the Alzheimer type — comparison of clinical classifications....Pages 79-90
Problems of differential diagnosis between depressive pseudodementia and Alzheimer’s disease....Pages 91-95
The neuropathological diagnosis of Alzheimer disease....Pages 97-118
The progression of the lesions in Alzheimer disease: insights from a prospective clinicopathological study....Pages 119-126
Evolution of neuronal changes in the course of Alzheimer’s disease....Pages 127-140
The cytoskeleton in Alzheimer disease....Pages 141-145
Mechanisms of synaptic pathology in Alzheimer’s disease....Pages 147-158
Proteolytic processing of Alzheimer’s disease associated proteins....Pages 159-167
Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles....Pages 169-180
Presenilins and Alzheimer’s disease: the role of Aβ42....Pages 181-184
Biological markers for the diagnosis of Alzheimer’s disease....Pages 185-197
Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer’s disease....Pages 199-207
Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer’s disease....Pages 209-221
Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing....Pages 223-235
Positron emission tomography for diagnosis of Alzheimer’s disease and vascular dementia....Pages 237-250
Current diagnostic methods and outcome variables for clinical investigation of Alzheimer’s disease....Pages 251-254
Perspectives in clinical Alzheimer’s disease research and the development of antidementia drugs....Pages 255-275
The role of glutamate in dementia....Pages 277-287
Neurotrophic activities and therapeutic experience with a brain derived peptide preparation....Pages 289-298
Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats....Pages 299-311
The influence of Cerebrolysin® and E021 on spatial navigation of 24-month-old rats....Pages 313-321
Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors....Pages 323-331
Antioxidant systemic effect of short-term Cerebrolysin® administration....Pages 333-341
Can Cerebrolysin® influence chronic deterioration of spatial learning and memory?....Pages 343-349
Cerebrolysin® protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia....Pages 351-361
Further evidence that Cerebrolysin® protects cortical neurons from neurodegeneration in vitro....Pages 363-372
Influence of BDNF and FCS on viability and programmed cell death (PCD) of developing cortical chicken neurons in vitro....Pages 373-384
Dose-dependent effects of Cerebrolysin® on EEG and short term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia....Pages 385-398
Back Matter....Pages 399-407